Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sosei Group ( (JP:4565) ) has issued an announcement.
Nxera Pharma, a Tokyo-listed biopharma group, has adjusted the issuance of new shares under its No. 18 and No. 20 Restricted Stock Unit plans following partial forfeiture by four planned recipients. The total number of shares to be issued has been reduced from 736,190 to 729,558, with corresponding decreases in the total payment amounts and in the number of allottees across directors, executives and employees.
The payment for the RSU-related share issuance was completed on May 18, 2026, with the per-share payment amount unchanged at ¥1,011 for both plans. The move modestly trims expected equity-based compensation dilution while maintaining the company’s stock-based incentive framework for leadership and staff, signaling continued reliance on RSUs to align management and employee interests with shareholders.
The most recent analyst rating on (JP:4565) stock is a Buy with a Yen1400.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
More about Sosei Group
Nxera Pharma is a technology-powered biopharmaceutical company focused on developing new specialty medicines for patients with unmet medical needs in Japan and globally. It operates a next-generation commercial business in Japan and the broader APAC region, leveraging its NxWave GPCR structure-based drug discovery platform and a pipeline advanced internally and through partnerships from hubs in Japan, the UK, Switzerland and South Korea.
Average Trading Volume: 1,051,774
Technical Sentiment Signal: Hold
Current Market Cap: Yen107.5B
For a thorough assessment of 4565 stock, go to TipRanks’ Stock Analysis page.